CTOs on the Move

Meridian HealthCare

www.meridianhealthcare.net

 
Meridian Healthcare provides high quality care and services to older people in the UK. With care centres spread across the North of England, Meridian cares for over 1400 residents and many more day care clients. In our annual Customer Satisfaction Survey, well over 95% of families are keen to point out that they would recommend us for respite and long term care. We provide nursing, residential and specialist dementia care as well as day care services. Our residents may fund themselves or be funded wholly or partly by their local authorty. Our staff are well trained and undergo a range ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Green River Regional Mental Health Mental Retardation Board Inc

Green River Regional Mental Health Mental Retardation Board Inc is a Owensboro, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest Behavioral and Health Services

Our Mission: We Inspire People to Feel Better and Reach Their Potential` Through Helping People Discover Their Strengths, We Improve Our Communities` Southwest Behavioral Health Services employs over 900 full-time staff and an additional workforce available from part-time positions and contracts` Staff and volunteers reflect the cultural diversity of the community` SBH is governed by a Board of Directors comprised of approximately 15 community volunteers` Our service area includes the Phoenix metropolitan area, rural Maricopa County, Gila, Pinal, Mohave, Coconino, and Yavapai Counties` SBH has assumed a leadership role in development and delivery of services in the areas of housing, residential care, prevention services, outpatient services to children, incarcerated persons and dually diagnosed adults (SMI/SA)` Over the past several years, Southwest Behavioral Health Services has experienced rapid growth of its behavioral health programs` SBH has developed a reputation as an innovative leader in behavioral health` Our services are client directed-outcome informed, evidence-based and include treatment of co-occurring disorders, the FAST model in prevention services, the Arizona Treatment Initiative for children and families, and the Recovery Model for persons with serious mental illness`

AZTherapies, Inc.

AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions.

North Carolina Department of Environment and Natural Resources

The N.C. Department of Environment and Natural Resources (DENR) is the lead stewardship agency for the preservation and protection of North Carolina's outstanding natural resources. The organization, which has offices from the mountains to the coast, administers regulatory programs designed to protect air quality, water quality, and the public's health. DENR also offers technical assistance to businesses, farmers, local governments, and the public and encourages responsible behavior with respect to the environment through education programs provided at DENR facilities and through the state's school system. Through its natural resource divisions, DENR works to protect fish, wildlife and wilderness areas. The agency's activities range from helping to make sure drinking water is safe to managing state parks and forests for safe and enjoyable outdoor recreation experiences.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.